---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-24-000114"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:05:16.067474+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q2 net loss $16.2M; cash $88.6M; RLYB212 Phase 2 on track for Q4 2024

## Summary
- Q2 net loss $16.2M ($0.37/share) vs $18.6M ($0.46/share) in Q2 2023.
- Revenue $0.3M from J&J collaboration; no revenue in prior year.
- Cash, equivalents, and securities $88.6M as of June 30, expecting runway into mid-2026.
- RLYB212 Phase 2 trial in pregnant women at risk of FNAIT remains on track to start Q4 2024.
- Epidemiological analysis estimates >30,000 higher-risk pregnancies/year in North America and major European countries, 40% above prior estimates.

## SEC filing metadata
- accession: 0001739410-24-000114
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000114/0001739410-24-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000114/rlyb-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-24-000114
- JSON: https://secwatch.observer/filing/0001739410-24-000114.json
- Plain text: https://secwatch.observer/filing/0001739410-24-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.